BioCryst Pharmaceuticals, Inc. (BCRX) said, based on the ongoing discussions with the National Institute of Allergy and Infectious Diseases, the company expects NIAID to continue their support for the development of galidesivir with a focus on biodefense threats, such as Marburg virus disease, and to discontinue the pursuit of a COVID-19 indication for galidesivir.

Create Account

Dark

chart

exchange

Check out our Level2View

BioCryst Pharmaceuticals, Inc. (BCRX) said, based on the ongoing discussions with the National Institute of Allergy and Infectious Diseases, the company expects NIAID to continue their support for the development of galidesivir with a focus on biodefense threats, such as Marburg virus disease, and to discontinue the pursuit of a COVID-19 indication for galidesivir.

RTTNews | Dec 22, 2020 07:15AM EST

07:15 Tuesday, December 22, 2020 (RTTNews.com) - BioCryst Pharmaceuticals, Inc. (BCRX) said, based on the ongoing discussions with the National Institute of Allergy and Infectious Diseases, the company expects NIAID to continue their support for the development of galidesivir with a focus on biodefense threats, such as Marburg virus disease, and to discontinue the pursuit of a COVID-19 indication for galidesivir.

The company said data from part 1 of a clinical trial of galidesivir showed that galidesivir was safe and generally well tolerated in patients infected with SARS-CoV-2.

Read the original article on RTTNews ( https://www.rttnews.com/3155603/biocryst-expects-niaid-to-discontinue-pursuit-of-covid-19-indication-for-galidesivir.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved